AIB1 is a novel target of the high-risk HPV E6 protein and a biomarker of cervical cancer progression.

Saved in:
Bibliographic Details
Title: AIB1 is a novel target of the high-risk HPV E6 protein and a biomarker of cervical cancer progression.
Authors: Miller J; Department of Pathology, Center for Cell Reprogramming, Georgetown University Medical School, Washington, District of Columbia, USA., Dakic A; Department of Pathology, Center for Cell Reprogramming, Georgetown University Medical School, Washington, District of Columbia, USA., Spurgeon M; McArdle Laboratory for Cancer Research, Department of Oncology, University of Wisconsin-Madison School of Medicine and Public Health, Madison, Wisconsin, USA., Saenz F; Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical School, Washington, District of Columbia, USA., Kallakury B; Department of Pathology, Center for Cell Reprogramming, Georgetown University Medical School, Washington, District of Columbia, USA., Zhao B; Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA., Zhang J; Department of Radiation Oncology, Wexner Medical Center, The Ohio State University, Columbus, Ohio, USA.; The James Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio, USA., Zhu J; Department of Pathology, Wexner Medical Center, The Ohio State University, Columbus, Ohio, USA., Ma Q; The James Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio, USA.; Department of Biomedical Informatics, College of Medicine, The Ohio State University, Columbus, Ohio, USA., Xu Y; Computational Systems Biology Lab, Department of Biochemistry and Molecular Biology and Institute of Bioinformatics, The University of Georgia, Athens, Georgia, USA., Lambert P; McArdle Laboratory for Cancer Research, Department of Oncology, University of Wisconsin-Madison School of Medicine and Public Health, Madison, Wisconsin, USA., Schlegel R; Department of Pathology, Center for Cell Reprogramming, Georgetown University Medical School, Washington, District of Columbia, USA., Riegel AT; Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical School, Washington, District of Columbia, USA., Liu X; Department of Pathology, Center for Cell Reprogramming, Georgetown University Medical School, Washington, District of Columbia, USA.; The James Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio, USA.; Department of Pathology, Wexner Medical Center, The Ohio State University, Columbus, Ohio, USA.
Source: Journal of medical virology [J Med Virol] 2022 Aug; Vol. 94 (8), pp. 3962-3977. Date of Electronic Publication: 2022 Apr 27.
Publication Type: Journal Article; Research Support, N.I.H., Extramural
Journal Info: Publisher: Wiley-Liss Country of Publication: United States NLM ID: 7705876 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1096-9071 (Electronic) Linking ISSN: 01466615 NLM ISO Abbreviation: J Med Virol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1096-9071
DOI:10.1002/jmv.27795